Hunter Perkins Capital Management LLC Sells 22,056 Shares of Johnson & Johnson $JNJ

Hunter Perkins Capital Management LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 41.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,489 shares of the company’s stock after selling 22,056 shares during the period. Johnson & Johnson comprises approximately 1.5% of Hunter Perkins Capital Management LLC’s investment portfolio, making the stock its 18th largest holding. Hunter Perkins Capital Management LLC’s holdings in Johnson & Johnson were worth $6,517,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. SOA Wealth Advisors LLC. lifted its holdings in Johnson & Johnson by 0.7% during the third quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock worth $1,371,000 after acquiring an additional 53 shares during the period. Ethos Financial Group LLC raised its stake in Johnson & Johnson by 0.6% in the 3rd quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock valued at $1,689,000 after acquiring an additional 53 shares during the period. Pinnacle Holdings LLC boosted its position in Johnson & Johnson by 0.5% during the third quarter. Pinnacle Holdings LLC now owns 11,214 shares of the company’s stock worth $2,079,000 after purchasing an additional 54 shares during the period. Bouchey Financial Group Ltd increased its stake in shares of Johnson & Johnson by 0.8% in the third quarter. Bouchey Financial Group Ltd now owns 7,249 shares of the company’s stock worth $1,344,000 after purchasing an additional 54 shares in the last quarter. Finally, Boltwood Capital Management raised its position in shares of Johnson & Johnson by 1.3% in the fourth quarter. Boltwood Capital Management now owns 4,263 shares of the company’s stock valued at $882,000 after purchasing an additional 54 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on JNJ shares. Leerink Partners raised their price objective on shares of Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a report on Thursday, January 22nd. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a research note on Thursday, January 22nd. Freedom Capital cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. Finally, TD Cowen upped their price target on Johnson & Johnson from $222.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $236.91.

Insiders Place Their Bets

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the sale, the executive vice president directly owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is owned by insiders.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Royalty Pharma agreed to provide $500 million of R&D co‑funding for JNJ‑4804, a novel co‑antibody targeting IL‑23 and TNF; the deal de‑risks development costs, validates the program and accelerates immunology exposure for J&J. Royalty Pharma and J&J partner to develop autoimmune treatment Johnson & Johnson’s JNJ-4804 Deal Adds Weight To Immunology Story
• Positive Sentiment: J&J presented first randomized Phase 2 data for JNJ‑1900 (NBTXR3) in stage‑3 inoperable lung cancer at a major conference — early positive clinical readouts support the oncology pipeline and partner collaborations. NANOBIOTIX Announces Presentation of First Data
• Positive Sentiment: Johnson & Johnson MedTech shared favorable findings for the Impella CP device in left‑ventricular support at ACC, which may support near‑term MedTech revenue momentum and competitive positioning. Johnson & Johnson MedTech shares findings for Impella CP
• Positive Sentiment: Royal Bank of Canada reaffirmed an “outperform” rating and a $255 price target, providing analyst backing that supports upside expectations versus current levels. RBC reaffirmation / Benzinga
• Positive Sentiment: Multiple outlets highlighted J&J as a top dividend/defensive stock and noted an upcoming dividend increase window — this bolsters demand from income and defensive investors given J&J’s low beta and long dividend history. This is Why Johnson & Johnson is a Great Dividend Stock Dividend increases coverage
• Neutral Sentiment: Industry research forecasts growth in the non‑muscle invasive bladder cancer market and lists J&J among leading competitors — a positive long‑term market backdrop but not an immediate catalyst. Non‑Muscle Invasive Bladder Cancer Market report

Johnson & Johnson Stock Performance

Shares of JNJ opened at $242.22 on Tuesday. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The company has a market cap of $583.40 billion, a PE ratio of 21.92, a price-to-earnings-growth ratio of 2.37 and a beta of 0.34. The stock has a 50-day moving average price of $237.87 and a 200-day moving average price of $211.39.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The business had revenue of $24.28 billion for the quarter. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend was Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 47.06%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.